1. Approval of Unaudited Financial Results

The Board approved the unaudited financial results (standalone and consolidated) for the quarter ended 30th June, 2026. The results, along with the limited review report from the statutory auditors, B S R & Co. LLP, were enclosed as Annexure 1 to the disclosure. The financial results were made available on the company's website, www.innovacaptab.com, in compliance with Regulation 46 of the Listing Regulations.

2. Adoption of Amended Materiality Policy

The Board approved amendments to the company's Policy for Determination of Materiality of Events or Information. This amendment was made to align the policy with recent notifications and amendments specified in the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The amended policy was made available on the company's website, constituting compliance with Regulation 30(4)(ii).

3. Revision of Financial Statements for FY26

The disclosure notes that subsequent to the approval of the standalone and consolidated financial statements for the year ended 31st March, 2026, by the Board on 07th May, 2026, certain inadvertent errors were identified. These errors were found in the standalone and consolidated financial statements, including in the statements of entities within the group. The company is in the process of making necessary corrections to these financial statements prior to their adoption at the ensuing Annual General Meeting. The matter is under consideration and will be placed before the Board at its next meeting. It was explicitly stated that these errors do not have any material impact on the standalone and consolidated financial results for the quarter ended 30th June, 2026, or on the comparative information presented therein. Requisite disclosures will be made to the stock exchanges upon conclusion of the Board's approval.

Financial Results Overview (Consolidated)

The reviewed unaudited consolidated financial results for the quarter ended 30 June 2026 are for Innova Captab Limited and its subsidiaries: Univentis Medicare Limited, Sharon Bio-Medicine Limited, and Univentis Foundation.

  • Total Income: ₹4,728.59 million (Q1 FY26: ₹4,493.65 million; Q2 FY25: ₹3,560.25 million; FY26: ₹16,374.38 million)
  • Total Expenses: ₹4,138.74 million (Q1 FY26: ₹3,986.90 million; Q2 FY25: ₹3,133.48 million; FY26: ₹14,491.74 million)
  • Profit Before Tax: ₹589.85 million (Q1 FY26: ₹506.75 million; Q2 FY25: ₹426.77 million; FY26: ₹1,882.64 million)
  • Total Tax Expense: ₹148.59 million (Q1 FY26: ₹125.92 million; Q2 FY25: ₹116.62 million; FY26: ₹473.47 million)
  • Profit for the Period: ₹441.26 million (Q1 FY26: ₹380.83 million; Q2 FY25: ₹310.15 million; FY26: ₹1,409.17 million)
  • Total Comprehensive Income for the Period: ₹442.95 million (Q1 FY26: ₹383.27 million; Q2 FY25: ₹310.19 million; FY26: ₹1,413.23 million)
  • Paid-up Equity Share Capital: ₹2.2575 million (face value of ₹10 per share)
  • Basic Earnings Per Share (₹): 7.71 (Q1 FY26: 6.65; Q2 FY25: 5.42; FY26: 24.63)

The group has one reportable segment: "Drugs and pharmaceutical products." The figures for the quarter ended 31 March 2026 are balancing figures between the audited annual figures and the previously published unaudited year-to-date figures up to the third quarter of FY26.

Financial Results Overview (Standalone)

The reviewed unaudited standalone financial results for the quarter ended 30 June 2026 are for Innova Captab Limited.

  • Total Income: ₹4,031.78 million (Q1 FY26: ₹3,609.57 million; Q2 FY25: ₹2,912.94 million)
  • Total Expenses: ₹3,601.44 million (Q1 FY26: ₹3,330.22 million; Q2 FY25: ₹2,640.02 million)
  • Profit Before Tax: ₹430.34 million (Q1 FY26: ₹279.35 million; Q2 FY25: ₹272.92 million)
  • Total Tax Expense: ₹109.74 million (Q1 FY26: ₹67.73 million; Q2 FY25: ₹69.97 million)
  • Profit for the Period: ₹320.60 million (Q1 FY26: ₹211.62 million; Q2 FY25: ₹202.95 million)
  • Total Comprehensive Income for the Period: ₹319.34 million (Q1 FY26: ₹215.03 million; Q2 FY25: ₹200.23 million)
  • Paid-up Equity Share Capital: ₹572.25 million (face value of ₹10 per share)
  • Basic Earnings Per Share (₹): 5.60 (Q1 FY26: 3.70; Q2 FY25: 3.55)

The company has one reportable segment: "Drugs and pharmaceutical products." The figures for the quarter ended 31 March 2026 are balancing figures.

Auditor's Review Conclusion

The statutory auditors, B S R & Co. LLP, issued an unmodified review conclusion on both the unaudited consolidated and standalone financial results for the quarter ended 30 June 2026. For the consolidated results, the review of one subsidiary (Univentis Foundation, with revenue of ₹Nil and net profit of ₹0.80 million for the quarter) was performed by another auditor, and the conclusion is based on that report.